You are here

  • Home
  • Archive
  • Volume 67, Issue 9
  • Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells

Article Text

Article menu
Download PDFPDF
Extended report
Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells
  1. L Salazar1,
  2. O Aravena1,
  3. P Abello1,
  4. A Escobar1,
  5. J Contreras-Levicoy1,
  6. N Rojas-Colonelli1,
  7. D Catalán1,
  8. A Aguirre1,
  9. R Zúñiga1,
  10. B Pesce1,
  11. C González2,
  12. R Cepeda2,
  13. M Cuchacovich3,
  14. M C Molina1,
  15. F Salazar-Onfray1,
  16. M Delgado4,
  17. R E Toes5,
  18. J C Aguillón1
  1. 1
    Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile
  2. 2
    Departamento de Patología Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile
  3. 3
    Sección de Reumatología, Departamento de Medicina, Hospital Clínico Universidad de Chile, Santiago, Chile
  4. 4
    Instituto de Parasitologia y Biomedicina, CSIC, Granada, Spain
  5. 5
    Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  1. J C Aguillón, Programa Disciplinario de Inmunología, ICBM, Facultad de Medicina, Universidad de Chile. Av. Independencia 1027, Santiago, Chile; jaguillo{at}med.uchile.cl

Abstract

Background: The use of regulatory or immature dendritic cells (DCs) as tools for modulating experimental rheumatoid arthritis is very recent. Tumour necrosis factor (TNF)-stimulated DCs have been shown to restore tolerance in experimental autoimmune encephalomyelitis and collagen-induced arthritis (CIA).

Objective: We investigated the capacity of short-term lipopolysaccharide (LPS)-stimulated DCs pulsed with type II collagen (CII) to induce tolerance against established CIA.

Methods: Bone marrow-derived DCs were generated in the presence of granulocyte monocyte colony-stimulating factor (GM-CSF). After CIA induction, mice were injected at day 35 with a single dose of 4- or 24-h LPS-stimulated DCs that had been loaded with CII (4hLPS/CII/DCs or 24hLPS/CII/DCs). Arthritis progression was monitored by clinical and histological evaluations.

Results: Flow cytometry of 4hLPS/CII/DCs showed intermediate CD40 and CD86 expression, lower than that of 24hLPS/CII/DCs (fully mature) and higher than that of CII/DCs (immature). A functional assay showed that 4hLPS/CII/DCs display increased endocytosis ability with respect to 24hLPS/CII/DCs, indicating a semimature state. The single inoculation of 4hLPS/CII/DCs in mice with established CIA reduced disease severity significantly over time. Histological evaluation of mice treated with 4hLPS/CII/DCs revealed diminished inflammatory synovitis, cartilage damage and fibrosis. Co-cultures of DCs with splenocytes from CIA mice showed that collagen-specific interferon (IFN)γ production was dramatically inhibited by 4hLPS/CII/DCs. 4hLPS/CII/DCs were high IL10 producers, which could explain the inhibition of arthritis progression in mice receiving this treatment because neither antibodies nor regulatory CD4+CD25+Foxp3+ T lymphocytes were demonstrated to be involved.

Conclusion: Short-term LPS-modulated DCs inoculation interferes with CIA progression when loaded with CII.

https://doi.org/10.1136/ard.2007.072199

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This study was supported by Fondecyt-Chile (104-0860 and 107-0553).

    • Competing interests: None declared.

    • Ethics approval: All protocols were approved by the University of Chile Bioethics Committee.

    • LS, OA, AE, JC-L, N R-C, DC, AA, RZ, F S-O and JCA are members of the Millennium Nucleus on Immunology and Immunotherapy – Chile (P04/030-F).